Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (DE:HTD)
BERLIN:HTD
Corcept Therapeutics (HTD) Stock Price & Analysis
1 Followers
HTD Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€19.40 - €31.60
Previous Close€22.56
Volume0.00
Average Volume (3M)209.00
Market Cap
€2.37B
Enterprise Value€2.03B
Total Cash (Recent Filing)$368.22M
Total Debt (Recent Filing)$151.00K
Price to Earnings (P/E)N/A
Beta-0.01
Next Earnings
Jul 31, 2024EPS Estimate
€0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding104,112,088
10 Day Avg. Volume0
30 Day Avg. Volume209
Standard Deviation0.16
R-Squared0.06
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)5.15
Price to Sales (P/S)13.84
Price to Cash Flow (P/CF)110.80
P/FCF Ratio110.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.20
Enterprise Value/Gross Profit4.26
Enterprise Value/Ebitda17.20
Forecast
1Y Price Target
€36.56Price Target Upside62.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Corcept Therapeutics News
PremiumCompany Announcements
Corcept Therapeutics Reveals Q1 2024 Financial Results and Update
PremiumPre-Earnings
Is CORT a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentCorcept's relacorilant shows promise with positive results in the Phase 3 Grace study for treating Cushing’s syndrome, potentially offering a more selective treatment with fewer adverse events.
Financial PerformanceCorcept has exceeded revenue expectations and maintains a robust cash position, which along with consistent share buy-backs, reflects management's confidence in the company's valuation and growth prospects.
Stock RecommendationWith strong buyers encouraged by highly statistically significant open-label data, analysts recommend a BUY rating for Corcept's stock, signaling confidence in its future performance.
Bears Say
Clinical Trial ReportingInvestors were surprised by the split fashion reporting of the GRACE trial data, with blind, randomized withdrawal phase results not yet available.
Legal IssuesDisappointing court ruling on litigation with Teva for Korlym, which enables generic entry that would cut into Corcept’s overall commercial Cushing’s syndrome franchise.
Patent ChallengesTeva's earlier generic entry than Corcept management's previously guided 2037 IP runway for Korlym's challenged patents could slow uptake of Corcept’s next-gen Cushing’s syndrome agent relacorilant.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
4.85% Other Institutional Investors
95.15% Public Companies and
Individual Investors
HTD FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was €19.40 and its highest was €31.60 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Jul 31, 2024 which is in 88 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on May 01, 2024. The company reported €0.233 earnings per share for the quarter, beating the consensus estimate of €0.205 by €0.028.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is €0.22.
How many shares outstanding does Corcept Therapeutics Inc. have?
Currently, no data Available
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of €0.233 in its last earnings report, beating expectations of €0.205. Following the earnings report the stock price went down -6.195%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 11M.
---
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€36.56 (62.04% Upside)
€36.56 (62.04% Upside)
Blogger Sentiment
Bullish
DE:HTD Sentiment 75%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.14%
12-Months-Change
Fundamentals
Return on Equity
21.75%
Trailing 12-Months
Asset Growth
6.16%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
HTD Earnings Call
Q1 2024
0:00 / 0:00
---
HTD Stock 12 Months Forecast
Average Price Target
€36.56
▲(62.04% Upside)
Technical Analysis
Corcept Therapeutics
―
Enanta Pharmaceuticals
―
Neurocrine
―
PTC Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering HTD
1 Year
1 Year Success Rate
12/17 ratings generated profit
1 Year Average Return
+7.72%
reiterated a buy rating 3 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +7.72% per trade.
---